In October, 2024，the New Drug Founders' Beijing Autumn Forum successfully concluded. Held on October 24th and co-hosted by the International Center For Science & Technology Innovation, the forum attracted leading figures from the biopharmaceutical industry, investment elites, and scientific pioneers from Beijing and across the nation. Participants engaged in lively and in-depth discussions on key topics, including emerging trends in policy regulation and industry development, how clinical and scientific research resources can empower industrial upgrading, and innovative practices in the central nervous system (CNS) field.

Dr. Tinghe Wu (CEO of P.S.K. Biosciences), Dr. Yongjie Zhuang (CEO of KCI BioTech), Dr. Jun Wei (CEO of iRegene), and Dr. Yuqiang Wang (CEO of Magpie Pharmaceuticals) participated in a roundtable discussion on innovative practices in the field of central nervous system (CNS) therapies.

Dr. Tinghe Wu said that exosomes, as drug delivery carriers, are facing unprecedented opportunities. In the field of targeted delivery for nucleic acid drugs, due to the limitations of LNP technology in targeted delivery capabilities, exosomes have opportunities to be used as nucleic acid drug delivery vehicles.

P.S.K. Biosciences has made breakthroughs in the CMC processes for nucleic acid drug loading. The company has achieved intracellular loading, overcoming bottlenecks in CMC process scale-up within the field and significantly enhancing loading efficiency.

In the field of MSC-derived exosome therapeutics, with overseas pipelines already submitting BLA applications, the advent of the "Exosome Drug Era" is imminent.P.S.K Bio's MSC-derived exosomes have been subdivided into subgroups, and the early indications include pulmonary fibrosis, thin endometrial repair, inflammatory bowel disease, etc. Some of them have been carried out in IIT clinical studies, and the first batch of patients have achieved significant results. In terms of CNS indications, the pharmacodynamic data are relatively positive.